COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of March 3, 2022
Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.
Tezepelumab Significantly Reduced Exacerbations in Patients with Severe Asthma, Respiratory Comorbidities
Tara Carr, MD, led a post hoc analysis of the NAVIGATOR phase 3 trial and presented data on tezepelumab efficacy in the vulnerable subgroup at the AAAAI 2022 meeting.
New CDC COVID-19 Community Level Metrics: Questions Patients May Have, Answers to Prep Clinicians
What questions might patients have about the CDC's new framework to measure COVID-19 community levels? Prep with our new slideshow.
Unmet Needs in US Migraine Headache Management: OVERCOME Study First Data
Findings on use of acute and preventive migraine therapy continue to reveal gaps with far more patients eligible than the proportions using either type.
Largest Genetic Study of Migraine to Date Identifies New Risk Factors
Researchers identified over 120 regions connected to risk of migraine, of which 86 were previously unknown.
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of March 2, 2022
CDC: Americans Living in Low- or Medium-Risk Areas Can Leave Mask at Home
Approximately 70% of Americans live in areas deemed low or medium risk for severe COVID-19 and can go maskless, according to new formula used by CDC.
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of March 1, 2022
CGM-measured Glucose Variability Associated with Diabetes Micro- and Macrovascular Complications
Glycemic variability and low time in range were associated with retinopathy, nephropathy, neuropathy, and CVD in a cohort of more than 20 000 persons, most with T2D.
Acute Migraine Treatment: A Guide to Medication Options
When choosing a migraine treatment for acute attack relief, the American Headache Society suggests following these steps.
Migraine Linked to Higher Risk of Pregnancy Complications in Preliminary Study
Researchers also found that women with migraine with aura had a higher risk of preeclampsia than those with migraine without aura.
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of February 28, 2022
Mepolizumab Clinically Effective Regardless of Type 2 Biomarker Status in Patients with Severe Asthma, Suggests Real-world Data
AAAAI 2022: Mepolizumab found effective in standard clinical care regardless of type 2 eosinophil biomarker status in patients with severe asthma.
Novel Agent for Severe Asthma Halves Exacerbation Rates Across Respiratory Comorbidities
Tezepelumab, a TSLP inhibitor, reduced asthma exacerbation rates in patients with severe uncontrolled disease across a range of respiratory comorbidities.
American Academy of Asthma, Allergy & Immunology 2022 News Highlights
AAAAI late-breaking science and findings that could change your treatment plan for patients with severe asthma, summarized by our editors for easy access.
Dupilumab Found to Improve Clinical, Histologic Aspects of Eosinophilic Esophagitis
AAAAI 2022: New study found patients with eosinophilic esophagitis who received dupilumab experienced clinically meaningful improvements in symptoms.
Dupilumab Significantly Decreased Itch and Hives in Patients with Chronic Spontaneous Urticaria
Dupilumab significantly reduced itch and hives in patients with H1 antihistamine-resistant chronic spontaneous urticaria, according to new research.
Asthma May be Linked to Severe COVID-19 but Not to Risk for Hospitalization
Patients with asthma who did require hospitalization for SARS-CoV-2 infection were at greater risk for intubation and remdesivir treatment, a new study reports.
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of February 25, 2022
Fostering Wellbeing in School-aged Children during COVID-19
How can clinicians help parents of school-aged children foster wellbeing now that pediatric COVID-19 vaccination and booster doses are recommended?
